Filing Flows › Pacira BioSciences (PCRX) › Bupivacaine liposome injectable suspension revenue
Pacira BioSciences (PCRX) Bupivacaine liposome injectable suspension revenue by quarter
Pacira BioSciences' Bupivacaine liposome injectable suspension revenue was $1.2M in Q3 2026 (third quarter 2026), -63% from Q2 2026. Over the last 7 quarters it ranged from $508K (Q2 2025) to $3.2M (Q2 2026).
| Quarter | Bupivacaine liposome injectable suspension revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.2M | -63% | -56% |
| Q2 2026 | $3.2M | +177% | +533% |
| Q1 2026 | $1.2M | +4% | -55% |
| Q4 2025 | $1.1M | -59% | — |
| Q3 2025 | $2.7M | +430% | — |
| Q2 2025 | $508K | -80% | — |
| Q1 2025 | $2.6M | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' Bupivacaine liposome injectable suspension revenue?
Pacira BioSciences' Bupivacaine liposome injectable suspension revenue was $1.2M in Q3 2026 (third quarter 2026), -63% from Q2 2026.
How has Pacira BioSciences' Bupivacaine liposome injectable suspension revenue changed?
Over the last 7 quarters it ranged from $508K (Q2 2025) to $3.2M (Q2 2026).